| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT04776980 Details | 2022-09-16 Interventional | 1 | 0 | Ferrosoferric O… Brain Neoplasms Glioblastoma Neoplasms Brain Tumor, Ad… Brain Tumor, Pr… Brain Tumor, Re… Glioblastoma Mu… | PI decision to close study - | |||
| NCT04089852 Details | 2022-09-16 Interventional | 2/3 | 0 | Nitrous Oxide Adolescent Heal… Analgesia Contraceptive D… Gynecology Long-Acting Rev… | Not able to perform intervention in current physical clinic location - | |||
| NCT04398134 2019-004902-85 Details | 2022-09-15 Interventional | 2 | 88 | Entecavir Hepatitis Hepatitis A Hepatitis B Hepatitis B, Ch… Hepatitis, Chro… Chronic Hepatit… | Study stopped due to a safety signal of drug-induced liver injury in subjects receiving 2158 Study ABI-H2158-201 was terminated early due to alanine aminotransferase (ALT) elevations among study participants who received ABI-H2158 (and not among those who received PBO). Further details on these events are described in the results section below. In the absence of an alternative etiology for the ALT elevations, further clinical development of ABI-H2158 was terminated by the Sponsor. | |||
| NCT03551522 Details | 2022-09-15 Interventional | 2 | 181 | Seladelpar Fatty Liver Non-alcoholic F… NASH - Nonalcoh… | unexpected histological findings - | |||
| NCT04650282 Details | 2022-09-14 Interventional | 2 | 2 | Lidocaine Ganglion Cysts Headache Concussion | Reassignment of PI to more intense clinical obligations prevents continuation of the trial. - | |||
| NCT01615510 Details | 2022-09-14 Interventional | 1 | 24 | Tapentadol Hyperalgesia Allodynia Pain | - - | |||
| NCT03960125 Details | 2022-09-13 Interventional | 1 | 0 | Imipramine Microvesicle Pa… Photodynamic Th… | The PI decided to move in another direction with his research. - | |||
| NCT03894540 2018-003681-13 Details | 2022-09-13 Interventional | 1 | 22 | Paclitaxel Pembrolizumab Neoplasms Solid Tumor | Following an internal portfolio review, Ipsen has made the decision to terminate study
D-US-60090-001. Ipsen would like to highlight that early termination was not due to any safety
or tolerability issues with IPN60090 The study was terminated by the sponsor following an internal portfolio review during the dose escalation phase (Part A). The early termination was not due to any safety or tolerability issues with IPN60090. | |||
| NCT05089461 Details | 2022-09-10 Interventional | 2 | - | Mitoxantrone Neoplasms Advanced Malign… | sponsor decided to stop - | |||
| NCT03955471 Details | 2022-09-10 Interventional | 2 | 41 | Dostarlimab Niraparib Carcinoma, Ovar… Ovarian Neoplas… | The study will not resume based on the results of a planned interim analysis that showed
futility - | |||
| NCT02203513 Details | 2022-09-10 Interventional | 2 | 111 | Prexasertib Breast Neoplasm… Carcinoma, Ovar… Ovarian Neoplas… Prostatic Neopl… Triple Negative… Breast Cancer Ovarian Cancer Prostate Cancer | Eli Lilly prematurely terminated the study. - | |||
| NCT04040621 2018-002841-12 Details | 2022-09-09 Interventional | 1 | 4 | Avibactam Avibactam, ceft… Ceftazidime Healthcare-Asso… Pneumonia Hospitalized Ch… | Following regulatory consultation, the Sponsor has decided to terminate the study and analyze
the current dataset. The decision to terminate was solely based on a business decision, not due
to safety concerns. Only 4 participants were enrolled in this study. Outcome measures and AE data were not reported by cohort as planned in the protocol because doing so would risk re-dentification of the individual participants. | |||
| NCT03998709 Details | 2022-09-09 Interventional | 4 | 0 | Somatostatin Soybean oil, ph… Healthy | results from other study suggest no good reason to proceed - | |||
| NCT04516941 Details | 2022-09-08 Interventional | 3 | [7 Refs] | 60 | Colchicine Edoxaban COVID-19 Infections Severe Acute Re… SARS-CoV Infect… | Insufficient rate of patient accrual and newly available scientific evidence - | ||
| NCT04899232 Details | 2022-09-07 Interventional | 2 | 52 | Antithrombin II… Antithrombins Antithrombin II… COVID-19 Communicable Di… Infections Covid19 | There are fewer potential patients and an early conclusion of the study would be beneficial in
an attempt to finish in a reasonable time and keep the cohorts homogenous. With decreased Coronavirus disease of 2019 (COVID-19) cases, enrollment slowed leading to the early termination of the trial; the target number of 75 enrolled patients was not reached. Hesitancy to participate in the trial was noted. | |||
| NCT05008913 Details | 2022-09-06 Interventional | 1 | 2 | Adavosertib Advanced Solid … | Study terminated because the clinical development programme for Adavosertib has been
discontinued - | |||
| NCT04949425 Details | 2022-09-02 Interventional | 1 | 3 | Adavosertib Neoplasms Advanced Solid … | Study terminated because the clinical development programme for Adavosertib has been
discontinued - | |||
| NCT04985136 Details | 2022-09-01 Interventional | 3 | 1 | Apatinib Sorafenib Carcinoma Carcinoma, Hepa… Advanced Hepato… | Sponsor R & D Strategy Adjustment - | |||
| NCT04909515 Details | 2022-09-01 Interventional | 2 | 0 | Isotretinoin Neuroblastoma | Study terminated due to business priorities - | |||
| NCT04133480 Details | 2022-09-01 Interventional | 4 | 0 | Cannabidiol Lennox Gastaut … Lennox-Gastaut … | The decision to withdraw the study was based on pandemic-related concerns of conducting a Phase
IV study requiring multiple clinic visits when medication is commercially available. The study
was withdrawn before any participants were recruited. - |